Article
Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C.
Human genetics - 1 Mar 2015
Iio Etsuko, Matsuura Kentaro, Nishida Nao, Maekawa Shinya, Enomoto Nobuyuki, Nakagawa Mina, Sakamoto Naoya, Yatsuhashi Hiroshi, Kurosaki Masayuki, Izumi Namiki, Hiasa Yoichi, Masaki Naohiko, Ide Tatsuya, Hino Keisuke, Tamori Akihiro, Honda Masao, Kaneko Shuichi, Mochida Satoshi, Nomura Hideyuki, Nishiguchi Shuhei, Okuse Chiaki, Itoh Yoshito, Yoshiji Hitoshi, Sakaida Isao, Yamamoto Kazuhide, Watanabe Hisayoshi, Hige Shuhei, Matsumoto Akihiro, Tanaka Eiji, Tokunaga Katsushi, Tanaka Yasuhito
Abstract excerpt
Cytopenia during interferon-based (IFN-based) therapy for chronic hepatitis C (CHC) often necessitates reduction of doses of drugs and premature withdrawal from therapy resulting in poor response to treatment. To identify genetic variants associated with IFN-induced neutropenia, we conducted a genome-wide association study (GWAS) in 416 Japanese CHC patients receiving IFN-based therapy. Based on the results, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.